aha, yep, early 2015. It cannot really start early 2015 based on the list of things yet to be done. And the list of things that need to be done that are not on the list.

Has anything related to AMBS started even close to on time? Seriously.

AMBS the cult stock.

They did not mention in the release that they are also going after grants for this project, which will also take some time, and implies that they do not have any grants for this yet, nor have they applied for them. They also do not note any communication with MJFF.

another chortle, and continued belly laughing. See, AMBS CEO has no clue how long it takes to start things because he has never done it.

Dr. Lowe should be President, he's done this and would represent the company in a professional manner. Noting the study would begin in 2014 and in 2015 in the same release is totally unprofessional, but par for the course.

1. Request pre-IND meeting with the FDA

2. Submit IND to the FDA

3. Obtain IND approval

4. Start enrolment for the Phase 2b PD LID clinical trial in the USA

5. Submit Phase 2b design to EMEA



6. Obtain agreement on Phase 2b trial design with EMEA

7. Start enrolment for the Phase 2b PD LID clinical trial in Europe

"We are very pleased that our Eltoprazine program has progressed so rapidly under the direction of Dr. Keywood and Dr. Lowe," said Gerald E. Commissiong. "The initiation of the Phase 2b trial in PD LID will mark a major milestone for Amarantus. We expect to be in the clinic for this important indication by early 2015. PD LID represents a significant unmet medical need for Parkinson's disease patients."

There you go, it says early 2015, not 2014 as it does earlier in the same release. ALL of the things in that list take time, more time than is claimed in this release.

LOL, LMAO, again

GC just confirmed what I had been telling you. They did not include the IRB approval. That does not happen overnight either.

I am really belly laughing about this. now a chortle. I may need to call 911.

"The ‘Fit for Purpose Flow Cytometry Assay Validation’ is the Analytical Performance Package (APP) that management has been alluding to as the critical set of experiments required to demonstrate that LymPro is a commercial-grade test with required reproducibility. Amarantus believes this initial work at ICON will cost less than $150,000 and data should be returned to the company in 6 to 8 weeks. We note that Amarantus is maintaining all intellectual property rights to LymPro at the current time. The agreement with ICON is simply a services agreement that gets the ball rolling on the CLIA process. This services agreement extends over four years and covers LymPro’s central laboratory requirements under CLIA. We note that under CLIA, only one laboratory facility can run a Laboratory Developed Test, so if once LymPro is cleared under CLIA ICON has meaningful upside as the contracted lab to run the test for Amarantus."

This is from Zack's. AMBS is paying ICON to set up Lympro. If this was a blockbuster test, the lab companies would have been busting down the doors to get to Lympro, AND they would have gotten main stream press coverage.

The coverage that they got from JN was farcical. JN is a paid talking head, willing to spew the company propaganda.

I finally took the time to get the reference, someone told me the other day that ICON paid AMBS, it is the other way around. Oh.

So, Lympro will not be much for a long time, and the Eltoprazine study will not be starting this year. Its starting date will depend on first getting a principal investigator and then getting the Principal to get the study past the IRBs at various institutions. And then there is the issue of grants. The company may have the money to pay for this, but if they cannot get a grant, it speaks to the PD community's urgency to do this study.

As I noted before, they do not have a principal investigator. It is almost October, the study can't start until the IRB meets and approves the study for each sight and they do not have a prinicipal yet.

They are looking at grants, that means they need money. It takes a long time to get grants, you just do not wave your hand and get a grant.

MJFF wants more data, iow, they are not going to fund this, because the data is coming from the IIb study, and no data will come before the IIb study.

If Lowe was phrasing the presentation, it would have been much more straightforward, as it is, you have to read between the lines, and also know how these things work.

I posted about this at the time, but you decided not to pay attention to it.

I did not say this, GC did in the ? period. Given GC's answers there is NO way that the ELtoprazine study can start this year.

This company is farcical, and seriously, any investor in biotech needs to know how things work before they pony up the dough.

ROFLOL

I found the reference in a few clicks. It is up to you to do your dd.

good dd is always important. I do my dd correctly. I am not a cultist.

Well, that is a range, it has already gotten to the high 8 cents the day of the second day of the crash ( see the chart on the Ihub page ) I would bet on 8 cents.

How are you drawing the line for the retracement of the head and shoulders?

email GC, he said it in his CC until I read that, I was thinking the study was on schedule. Don't look at me.

I already did. I posted on it the day of the conference call. You should be happy that I continue to post. Do your own dd. When I am wrong, let me know. So far, I have not been materially wrong.

Now, I did believe the company on this, because it was so close, but that proved not to be accurate.

Go through my posts, one by one, and read them, do a search on google, for the pertinent terms.

poor dd leads to poor results.

Look up the conference call notes posted by a user. Do your own due diligence as I do. I believe the notes were posted by tvset. You should know by now that when I post something, it is extremely well referenced. I would think that the conference call can be called up so that you can listen to it yourself.

I am not the one who noted difficulty funding the Eltoprazine study, it was GC in the Conference call. Before that, I was thinking that it was going ahead, without difficulty.

Seriously, this is not a laughing matter.

AMBS is even complaining about the cost of the IIb study for Eltoprazine. I am sure they have study funding problems. They can keep going around to conferences and funding poor science tiny studies, but they cannot fund a 200 person study on Eltoprazine, according to the company.

They do not need money if they are going to continue on this path, however, they need billions if they are actually going to do studies of note.

Yes, if there were hundreds of people in the study, it would be something. 72 is nothing, it is not even the minimum. It is an attempt at pr. It is horrible science.

ask any scientist, do not ask me or anyone on this board.

it is comical.

Everything about this company, except for Dr. Lowe is comical. Dr Lowe for President.

In the scheme of things, AMBS has money to keep doing what it is doing, which is really nothing. It cannot research anything with the money that it has available. Anyone who thinks they can do that is not looking at what pharma has to spend to research a compound. The number just for MANF is in the Billions.

So, I am sure that they need the additional shares. When the Lympro numbers turned up weak, and did not propel the stock to the dollars, they immediately announced the additional shares.

There was a reason that the Lympro data was rushed, they needed the money. That said, the numbers are consistent with past studies, even though the numbers were weak, so next to no money will be coming from Lympro.

and so on.

Bottom line, repeating for affect. AMBS has enough money to keep doing what its been doing, gather the IP rights for MANF, and send out PRs for another couple of years. That amounts to nothing in terms of getting MANF, or Eltoprazine, or P-16 to market.

At some point, they will be selling in order to make money and buy a sailboat, now, when they do that, everyone will make money as well, just not as much as if the actual products were taken to market.

Sell at the blow off top, buy at the 200 day MA. rinse and repeat. Biotech heaven. Biotech hell, buy when everyone else is buying, and then panic when the pps tanks. Ambs can be biotech heaven, or biotech hell depending on whether you know what to do with Biotech stocks in general.

After the RS occurs, there will not be a huge number of shares out there. They only have money to keep doing what they are doing until 2016. They do not have money to actually study MANF, and Eltoprazine.

Just how much of the possibly equity in MANF the company gets to keep remains to be seen.

Lympro will bring just a little bit of revenue at best, even in 2016. Serial mendacious behavior pervades the actions of AMBS management. I do like Dr Lowe however. I would put him in charge of the hole thing.

Two stickies disappeared. One was from the Twitter conference, and the other were the notes of a poster from the recent conference call. Could someone direct me to those posts please.

Interesting price action today. The pps tanked, BUT the 200 day MA held. That is the important part, and the pps recovered nicely off the 200 day MA.

Not really, the PR that I quoted almost guarantees a reverse split, explaining why a RS with Amarantus is different. Here comes the RS. At ten cents, they are looking at getting to $6 or so. So you do the math.

no one uplists at $2.

To me this says that we need more shares so that we can raise more money. There most certainly will be a reverse split.

"The Typical Problem with Reverse Splits, and why a Potential Reverse Split of Amarantus is Different

Of note, the Company did not submit a reverse split resolution to a vote of the shareholders at our September 22nd, 2014 shareholder meeting. The reason for this is that under the laws of the State of Nevada, the Company’s Board of Directors can implement a proportional reverse split of the common shares without the need for a shareholder vote. It is absolutely critical for shareholders to understand what this means and why a reverse split of the authorized shares with an equal and proportional reverse split of the common shares outstanding will protect shareholders from the typical outcome seen in reverse splits. Concurrently, it is important to note that the Company is fully aware of the potential negative outcome of reverse splits, and will only implement a reverse split in conjunction with a listing on a national exchange, where history tells us that we typically see an 18% increase in shareholder value, as opposed to typical reverse splits with no national listings that typically lead to an 18% decrease in shareholder value."

And Amarantus is different from the rest of the market.

The stock is currently valued at about the right level. It is VERY likely that development of MANF will NOT lead to that much shareholder value because AMBS does not have any money, or currency. Lympro did not pan out. Eltoprazine has no funding and no Principal investigator. MJFF wants more data on Eltoprazine before pulling the trigger.

I missed that, the MACD crossed over the wrong way a couple of days ago.

It seems that we got some new posters ( at least new this month ) came on, or back, after the CC, to say that everything was OK, but well, almost nothing is OK and there is nothing that you can do to change that.

Also, the market traded down after the conference call. I suppose that the market did not hear the words on the conference call correctly.

to make a lot of money. Buy at the 200 day MA, sell at the blow off top at the conference. rinse and repeat.

Also, I would think that a major deal would include replacing most of management. Now, that would be a GREAT thing for the shareholders, and I do not think it would be something that would keep a deal from happening.

Ok, according to the notes from the recent CC stickied in this board, every prediction in my sticky remains accurate except one. The Eltoprazine study cannot possibly get started on the original schedule for lack of funding and a principal investigator.

Keeping in mind that I am going by the notes from the CC stickied on this page, there will be minimal Lympro revenue in 2015. That does not support anything except an AMBS cult.

MANF continues to be very interesting, and as noted, it will depend on if AMBS can maintain much equity in MANF as they seek the BILLIONS of dollars needed to study that compound.

That is an interesting situation, because there will be a lot of study of MANF, but AMBS has no money.

Continued purchase of AMBS at or in this case, possibly below the 200 day MA with sales on the blow off peaks ( so far consistently related to conferences ) is the way to make the most money off of AMBS.

If they can make the change from penny stock and horrible management to listed stock with new management, then that would be unusual. The worth of MANF continues to RISE however, so things will be interesting.

It is telling that according to the notes from the CC, MJFF is balking on funding Eltoprazine. They do remember the rebuke they had to give AMBS, and they do remember that this class of compounds has terrible side effects in general.

p 16 is VERY interesting and worthy of investment based on the talk given at the C4CT. No investigator in his right mind would sign a final agreement with AMBS on this compound because they unless there is something that we do not see such a compound would start a HUGE bidding war amongst traditional pharma or could be the basis of a startup Biotech with its own IPO and what not. ( If they got help )

glta.

Well, the market reacted normally to the call. Sometimes, the pps goes up with this stock on bad news for interesting reasons. I look for it to go much below the 200 day MA.

No revenue from Lympro until 2016, at least ( where did I hear that before ) no funding for a study that was supposed to start in 2014, and no principal investigator for the Eltoprazine study. ( I really thought they would be able to start the study and said so, so I was wrong on that )

MANF revenue is five to ten years away with no cash to get them there.

No reason to think that they will be able to sign P 16 since they have no money, or any size, and it requires a billion dollars or so to bring to market, as will MANF. Given that there are several possible indications for MANF it will take several billion dollars to bring to market.

I hope that you sold on the blow off top. That was the selling opportunity of the year.

I will like AMBS at nine cents, or so. Then I can wait for the MANF pops.

per the notes taken and posted in a stickie, ICON gets a cut of undetermined size. I do not see where anyone is paying AMBS to get the rights to their test.

do the math, that means that they are going to test 150000 AD protocol participants a year. Aha, yep, no doubt about that one, unquestionably, not possible.

There is a stickie with the notes from the conference call.

This is nothing but more obfuscation and outright delay. Most notably, if first dose for the Eltoprazine study was due this year, the funding would be set, and the Principal investigator would be set among other things. I could go on, but not now.

If the pps trades up because of this CC then well, I would take that data to someone who understands it and go from there.

So, ah, no revenue this year, no money from Lympro, no, no, no?

They had the CC today? How much did they project in revenue for Lympro?

I heard that AMBS got a gazillion dollars for the Lympro test from their partner. Too bad the stock did not move.

MANF could be a real opportunity. It seems that they have no interest, or ability to do the research that will take ten to 20 years on MANF.

I do think they will sell and retire at some point, not for billions though.